Combination of Disulfiram and Copper-Cysteamine Nanoparticles for an Enhanced Antitumor Effect on Esophageal Cancer

Overview

Journal ACS Appl Bio Mater

Specialties Biomedical Engineering
Biotechnology

Date 2021 Jun 28

PMID 34179726

Citations 7

Authors

Yan Chang

Fang Wu

Nil Kanatha Pandey

Lalit Chudal

Meiying Xing

Xiaoli Zhang

Linh Nguyen

Xian Liu

J Ping Liu

Wei Chen

Zui Pan

Affiliations

Soon will be listed here.

Abstract

Esophageal cancer (EC) is the sixth leading cause of cancer deaths worldwide with a low 5-year survival rate. More effective chemotherapeutic drugs, either new or repurposing ones, are urgently needed. Disulfiram (DSF) is a safe and public domain drug for alcohol addiction treatment and later shown to have anti-cancer capability, especially when administrated together with copper. The present study is to test the hypothesis that a newly developed copper-cysteamine (Cu-Cy) nanoparticles (NPs) can enhance the anti-tumor effect of DSF on esophageal cancer with reduced risk of copper poisoning. Our results showed that Cu-Cy NPs could greatly facilitate DSF to inhibit cell proliferation in cultured human esophageal cancer cells. Interestingly, the combined inhibitory function could be further enhanced when DSF and Cu-Cy NPs were present at an optimal molar ratio of 1:4. The results of the change in physical color, UV-vis absorption and fluorescence spectra, X-ray diffraction patterns, and FTIR spectra from a mixture of DSF and Cu-Cy NPs suggest a possible reaction between DSF and Cu-Cy NPs and the formation of new materials. Furthermore, cellular mechanistic studies revealed that the combination of DSF and Cu-Cy NPs resulted in reactive oxygen species (ROS) accumulation, and blocked nuclear translocation of NF-ƙB (p65) in esophageal cancer cells. Moreover, in xenograft nude mice, combined administration of DSF and Cu-Cy NPs greatly inhibited tumor growth without noticeable histological toxicity, while any single agent at the same doses presented no inhibitory function. Together, this study demonstrates an effective anti-cancer function of combined treatment of DSF and Cu-Cy NPs in vitro and in vivo, which could be a promising new chemotherapy for esophageal cancer patients.

Citing Articles

Programmable "triple attack" cancer therapy through activation of disulfiram toxification combined with phototherapeutics.

He Q, Jia B, Luo Z, Wang Y, Zhang B, Liao T Chem Sci. 2024; 15(29):11633-11642.

PMID: 39055020 PMC: 11268515. DOI: 10.1039/d3sc05300h.

Combination of disulfiram and Copper-Cysteamine nanoparticles induces mitochondria damage and promotes apoptosis in endometrial cancer.

Yang L, Yao C, Su Z, Fang Y, Pandey N, Amador E Bioact Mater. 2024; 36:96-111.

PMID: 38440322 PMC: 10911931. DOI: 10.1016/j.bioactmat.2024.02.009.

A Review on the Antimutagenic and Anticancer Effects of Cysteamine.

Lee C Adv Pharmacol Pharm Sci. 2023; 2023:2419444.

PMID: 37731680 PMC: 10508993. DOI: 10.1155/2023/2419444.

Current advances in nanoformulations of therapeutic agents targeting tumor microenvironment to overcome drug resistance.

Fakhri S, Moradi S, Faraji F, Farhadi T, Hesami O, Iranpanah A Cancer Metastasis Rev. 2023; 42(3):959-1020.

PMID: 37505336 DOI: 10.1007/s10555-023-10119-w.

Advancing Cancer Therapy with Copper/Disulfiram Nanomedicines and Drug Delivery Systems.

Kang X, Jadhav S, Annaji M, Huang C, Amin R, Shen J Pharmaceutics. 2023; 15(6).

PMID: 37376016 PMC: 10302862. DOI: 10.3390/pharmaceutics15061567.

References

Gomes A, Fernandes E, Lima J . Fluorescence probes used for detection of reactive oxygen species. J Biochem Biophys Methods. 2005; 65(2-3):45-80. DOI: 10.1016/j.jbbm.2005.10.003. View

Zhu H, Zhang H, Jin F, Fang M, Huang M, Yang C . Elevated Orai1 expression mediates tumor-promoting intracellular Ca2+ oscillations in human esophageal squamous cell carcinoma. Oncotarget. 2014; 5(11):3455-71. PMC: 4116495. DOI: 10.18632/oncotarget.1903. View

Zhen X, Chudal L, Pandey N, Phan J, Ran X, Amador E . A powerful combination of copper-cysteamine nanoparticles with potassium iodide for bacterial destruction. Mater Sci Eng C Mater Biol Appl. 2020; 110:110659. PMC: 7100965. DOI: 10.1016/j.msec.2020.110659. View

Ma L, Zou X, Chen W . A new X-ray activated nanoparticle photosensitizer for cancer treatment. J Biomed Nanotechnol. 2014; 10(8):1501-8. DOI: 10.1166/jbn.2014.1954. View

Sah B, Wu J, Vanasse A, Pandey N, Chudal L, Huang Z . Effects of Nanoparticle Size and Radiation Energy on Copper-Cysteamine Nanoparticles for X-ray Induced Photodynamic Therapy. Nanomaterials (Basel). 2020; 10(6). PMC: 7353381. DOI: 10.3390/nano10061087. View

Orrenius S, Nobel C, van den Dobbelsteen D, Burkitt M, Slater A . Dithiocarbamates and the redox regulation of cell death. Biochem Soc Trans. 1996; 24(4):1032-8. DOI: 10.1042/bst0241032. View

Chen D, Cui Q, Yang H, Dou Q . Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res. 2006; 66(21):10425-33. DOI: 10.1158/0008-5472.CAN-06-2126. View

Pandey N, Chudal L, Phan J, Lin L, Johnson O, Xing M . A facile method for the synthesis of copper-cysteamine nanoparticles and study of ROS production for cancer treatment. J Mater Chem B. 2019; 7(42):6630-6642. DOI: 10.1039/c9tb01566c. View

Fan Z, Chang Y, Cui C, Sun L, Wang D, Pan Z . Near infrared fluorescent peptide nanoparticles for enhancing esophageal cancer therapeutic efficacy. Nat Commun. 2018; 9(1):2605. PMC: 6031624. DOI: 10.1038/s41467-018-04763-y. View

10.

Nosaka Y, Nosaka A . Generation and Detection of Reactive Oxygen Species in Photocatalysis. Chem Rev. 2017; 117(17):11302-11336. DOI: 10.1021/acs.chemrev.7b00161. View

11.

Liu Z, Xiong L, Ouyang G, Ma L, Sahi S, Wang K . Investigation of Copper Cysteamine Nanoparticles as a New Type of Radiosensitiers for Colorectal Carcinoma Treatment. Sci Rep. 2017; 7(1):9290. PMC: 5570927. DOI: 10.1038/s41598-017-09375-y. View

12.

Gupte A, Mumper R . Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev. 2008; 35(1):32-46. DOI: 10.1016/j.ctrv.2008.07.004. View

13.

Li H, Wang J, Wu C, Wang L, Chen Z, Cui W . The combination of disulfiram and copper for cancer treatment. Drug Discov Today. 2020; 25(6):1099-1108. DOI: 10.1016/j.drudis.2020.04.003. View

14.

Zhang Q, Guo X, Cheng Y, Chudal L, Pandey N, Zhang J . Use of copper-cysteamine nanoparticles to simultaneously enable radiotherapy, oxidative therapy and immunotherapy for melanoma treatment. Signal Transduct Target Ther. 2020; 5(1):58. PMC: 7225170. DOI: 10.1038/s41392-020-0156-4. View

15.

Wu W, Yu L, Jiang Q, Huo M, Lin H, Wang L . Enhanced Tumor-Specific Disulfiram Chemotherapy by Cu Chelation-Initiated Nontoxicity-to-Toxicity Transition. J Am Chem Soc. 2019; 141(29):11531-11539. DOI: 10.1021/jacs.9b03503. View

16.

Cui C, Chang Y, Zhang X, Choi S, Tran H, Penmetsa K . Targeting Orai1-mediated store-operated calcium entry by RP4010 for anti-tumor activity in esophagus squamous cell carcinoma. Cancer Lett. 2018; 432:169-179. PMC: 6070391. DOI: 10.1016/j.canlet.2018.06.006. View

17.

Sleire L, Forde H, Netland I, Leiss L, Skeie B, Enger P . Drug repurposing in cancer. Pharmacol Res. 2017; 124:74-91. DOI: 10.1016/j.phrs.2017.07.013. View

18.

Shrestha S, Wu J, Sah B, Vanasse A, Cooper L, Ma L . X-ray induced photodynamic therapy with copper-cysteamine nanoparticles in mice tumors. Proc Natl Acad Sci U S A. 2019; 116(34):16823-16828. PMC: 6708320. DOI: 10.1073/pnas.1900502116. View

19.

Chang Y, Jiang J, Chen W, Yang W, Chen L, Chen P . Biomimetic metal-organic nanoparticles prepared with a 3D-printed microfluidic device as a novel formulation for disulfiram-based therapy against breast cancer. Appl Mater Today. 2021; 18. PMC: 8570539. DOI: 10.1016/j.apmt.2019.100492. View

20.

Chudal L, Pandey N, Phan J, Johnson O, Lin L, Yu H . Copper-Cysteamine Nanoparticles as a Heterogeneous Fenton-Like Catalyst for Highly Selective Cancer Treatment. ACS Appl Bio Mater. 2022; 3(3):1804-1814. DOI: 10.1021/acsabm.0c00098. View